This study compares the efficacy of Glimepiride (a sulphonylurea) and Sitagliptin (a DPP-4 inhibitor) in improving glycaemic control in Type 2 diabetics inadequately managed on Metformin. Given the increasing prevalence of Type 2 diabetes globally, the findings could have significant implications for treatment protocols and market positioning of these drugs. The collaboration with Merck Sharp & Dohme LLC indicates potential commercial interest in the outcomes, particularly for Sitagliptin, which is already established in the market. The results may influence prescribing practices and competitive dynamics between sulphonylureas and DPP-4 inhibitors.